DNA damaging agents in ovarian cancer
Epithelial ovarian cancer (EOC) is very sensitive to upfront chemotherapy. This condition is attributable to defects in the DNA damage repair system. Agents that damage DNA are the main drugs used for its treatment. Many EOC cells have DNA repair deficiencies that confer susceptibility to these agen...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-08-01
|
| Series: | EJC Supplements |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1359634920300057 |
| _version_ | 1828867528027275264 |
|---|---|
| author | Maria-Pilar Barretina-Ginesta |
| author_facet | Maria-Pilar Barretina-Ginesta |
| author_sort | Maria-Pilar Barretina-Ginesta |
| collection | DOAJ |
| description | Epithelial ovarian cancer (EOC) is very sensitive to upfront chemotherapy. This condition is attributable to defects in the DNA damage repair system. Agents that damage DNA are the main drugs used for its treatment. Many EOC cells have DNA repair deficiencies that confer susceptibility to these agents. Platinum is the most important agent for first-line and also for relapses, together with other drugs that can be given as monotherapy or along with platinum or other drugs. Lately, the emerging role of PARP inhibitors has changed the landscape of opportunities for patients with EOC. All these strategies will be reviewed in this article. |
| first_indexed | 2024-12-13T05:12:41Z |
| format | Article |
| id | doaj.art-21eb0419620348c4a506fd84f2068004 |
| institution | Directory Open Access Journal |
| issn | 1359-6349 |
| language | English |
| last_indexed | 2024-12-13T05:12:41Z |
| publishDate | 2020-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EJC Supplements |
| spelling | doaj.art-21eb0419620348c4a506fd84f20680042022-12-21T23:58:30ZengElsevierEJC Supplements1359-63492020-08-01156772DNA damaging agents in ovarian cancerMaria-Pilar Barretina-Ginesta0Department of Medical Oncology, Catalan Institute of Oncology (ICO) Girona, Avinguda de França, s/n17007, Girona, Spain.; Department of Medical Oncology, Catalan Institute of Oncology (ICO) Girona, Girona Biomedical Research Institute (IDIBGI), Department of Medical Sciences, Medical School University of Girona (UdG), SpainEpithelial ovarian cancer (EOC) is very sensitive to upfront chemotherapy. This condition is attributable to defects in the DNA damage repair system. Agents that damage DNA are the main drugs used for its treatment. Many EOC cells have DNA repair deficiencies that confer susceptibility to these agents. Platinum is the most important agent for first-line and also for relapses, together with other drugs that can be given as monotherapy or along with platinum or other drugs. Lately, the emerging role of PARP inhibitors has changed the landscape of opportunities for patients with EOC. All these strategies will be reviewed in this article.http://www.sciencedirect.com/science/article/pii/S1359634920300057DNA damaging agentsOvarian cancerPlatinumParp inhibitors |
| spellingShingle | Maria-Pilar Barretina-Ginesta DNA damaging agents in ovarian cancer EJC Supplements DNA damaging agents Ovarian cancer Platinum Parp inhibitors |
| title | DNA damaging agents in ovarian cancer |
| title_full | DNA damaging agents in ovarian cancer |
| title_fullStr | DNA damaging agents in ovarian cancer |
| title_full_unstemmed | DNA damaging agents in ovarian cancer |
| title_short | DNA damaging agents in ovarian cancer |
| title_sort | dna damaging agents in ovarian cancer |
| topic | DNA damaging agents Ovarian cancer Platinum Parp inhibitors |
| url | http://www.sciencedirect.com/science/article/pii/S1359634920300057 |
| work_keys_str_mv | AT mariapilarbarretinaginesta dnadamagingagentsinovariancancer |